Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus

Table 2 Model input data on unit costs of medical care (in 2012 US dollars) ^a

Cost inputs	Cost base case value (range^b)	Source
Inpatient cost per day (general ward)	$1,973.7 ($1,480.3 to $2,467.1)^c	[24]
Inpatient cost per day (ICU)	$3,415.6 ($2,561.7 to $4,269.5)^c	[24]
Mechanical ventilation per day	$225.2 ($168.9 to $281.5)^c	[25]
Physician/attending/intensivist visit	$175.0	CPT 99233 [26]
Specialist inpatient visit	$251.2	CPT 99253 [26]
Laboratory test (serum creatinine levels)	$65.9	CPT 80069^d[26]
Laboratory test (serum vancomycin levels)	$36.3	CPT 80202^e[26]
Laboratory test (complete blood count)	$34.3	CPT 85025^d[26]
Outpatient parenteral antibiotic therapy/day	$204.2	[27]
Injection costs for administration	$7.6	[28]
IV linezolid 600 mg	$114.6 ($86.0 to $143.3)^c	[29]
IV vancomycin 1 g	$5.8 ($4.4 to $7.3)^c	[29]

^aCPT, Current procedural terminology; ID, Infectious disease; IV, Intravenous. All costs were adjusted to US dollars using medical care component of the US Consumer Price Index [24–29]. ^bRanges are provided for variables that were used in sensitivity analyses. γ-distribution was used for these variables for probabilistic sensitivity analysis. ^cArbitrary ±25% range was used. ^dBased on testing once every day (while in hospital) for both linezolid and vancomycin. ^eBased on testing once a week for only vancomycin.

ISSN: 1364-8535